Primary care physicians (PCPs) have the opportunity to make a difference in the opioid epidemic, as they are responsible for approximately 50% of opioid prescriptions. PCPs are well suited to manage chronic pain as they are adept at managing chronic disease and associated comorbidities, coordinating care, and applying a biopsychosocial approach to multimodal pain management. Incorporating best practice strategies for the evaluation of pain, integration of risk assessment tools, and ongoing patient education and monitoring will optimize safe and responsible prescribing.
In this free CME Snack, Dr. Gold Dr. Schmidt focus on the complexity of chronic pain and how best to manage it in the primary care setting and discuss how PCPs and their patients can work together to make informed decisions about their pain management plan.
At the end of this CME/CE activity, participants should be able to:
The following learning objectives pertain only to those requesting CNE or CPE credit:
Supported by an educational grant from Johnson & Johnson.
Physicians, dentists, physician assistants, nurse practitioners, nurses, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Gold has no disclosures to report.
Dr. Siegfried has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.